Eiger BioPharmaceuticals, Inc. logo

Eiger BioPharmaceuticals, Inc.

NASDAQ:EIGR

Overview | Financials
Company Name Eiger BioPharmaceuticals, Inc.
Symbol EIGR
Currency USD
Price 1.725
Market Cap 2,552,120
Dividend Yield 0%
52-week-range 1.1 - 43.35
Industry Biotechnology
Sector Healthcare
CEO Dr. David Apelian M.B.A., M.D., MBA, Ph.D.
Website https://www.eigerbio.com

An error occurred while fetching data.

About Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus

Related Stocks

Aadi Bioscience, Inc. logo

Aadi Bioscience, Inc.

AADI

1.76 USD

Talaris Therapeutics, Inc. logo

Talaris Therapeutics, Inc.

TALS

2.72 USD

Radius Health, Inc. logo

Radius Health, Inc.

RDUS

16.66 USD

Edgewise Therapeutics, Inc. logo

Edgewise Therapeutics, Inc.

EWTX

17.2 USD

Akero Therapeutics, Inc. logo

Akero Therapeutics, Inc.

AKRO

18.66 USD

LianBio logo

LianBio

LIAN

0.319 USD

Financials

Numbers are in millions USD

Numbers are in millions USD